Solid tumors targeted in new CAR T-Cell immunotherapy trial

(Seattle Children's) Seattle Children's has opened a chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory non-central nervous system EGFR-expressing solid tumors. In the phase 1 trial, STRIvE-01, cancer-fighting CAR T cells will target the EGFR protein expressed in many childhood sarcoma, kidney and neuroblastoma tumors.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news